Viruses,
Journal Year:
2024,
Volume and Issue:
16(8), P. 1294 - 1294
Published: Aug. 14, 2024
The
acquisition
or
reactivation
of
Epstein–Barr
virus
(EBV)
after
allogeneic
Hematopoietic
Stem
Cell
Transplant
(HSCT)
can
be
associated
with
complications
including
the
development
post-transplant
lymphoproliferative
disorder
(PTLD),
which
is
significant
morbidity
and
mortality.
A
number
risk
factors
for
PTLD
have
been
defined,
T-cell
depletion,
approaches
to
monitoring
EBV,
especially
in
high-risk
patients,
use
preemptive
therapy
upon
viral
activation
described.
Newer
therapies
preemption
treatment
PTLD,
such
as
EBV-specific
cytotoxic
T-cells,
hold
promise.
Further
studies
help
define
risks,
diagnosis,
EBV-related
are
needed
this
at-risk
population.
NIHR Open Research,
Journal Year:
2023,
Volume and Issue:
3, P. 20 - 20
Published: July 4, 2023
Background:
People
with
myalgic
encephalomyelitis/chronic
fatigue
syndrome
(ME/CFS)
experience
core
symptoms
of
post-exertional
malaise,
unrefreshing
sleep,
and
cognitive
impairment.
Despite
numbering
0.2-0.4%
the
population,
no
laboratory
test
is
available
for
their
diagnosis,
effective
therapy
exists
treatment,
scientific
breakthrough
regarding
pathogenesis
has
been
made.
It
remains
unknown,
despite
decades
small-scale
studies,
whether
individuals
different
types
ME/CFS
separated
by
onset-type,
sex
or
age.
Methods:
DecodeME
a
large
population-based
study
that
recruited
17,074
participants
in
first
3
months
following
full
launch.
Detailed
questionnaire
responses
from
UK-based
who
all
reported
being
diagnosed
health
professional
provided
an
unparalleled
opportunity
to
investigate,
using
logistic
regression,
severity
onset
type
significantly
associated
sex,
age,
illness
duration,
comorbid
conditions
symptoms.
Results:
The
well-established
sex-bias
among
patients
evident
initial
cohort:
83.5%
were
females.
What
was
not
known
previously
females
tend
have
more
comorbidities
than
males.
Moreover,
female,
older
over
10
years
are
greater
severity.
Five
examined
self-reported
data:
those
(i)
after
glandular
fever
(infectious
mononucleosis);
(ii)
COVID-19
infection;
(iii)
other
infections;
(iv)
without
infection
at
onset;
and,
(v)
where
occurrence
preceding
known.
Among
findings,
unknown
status
active
fibromyalgia
Conclusions:
differ
symptoms,
and/or
when
stratified
sex-at-birth
around
time
onset.
NIHR Open Research,
Journal Year:
2023,
Volume and Issue:
3, P. 20 - 20
Published: Aug. 21, 2023
People
with
myalgic
encephalomyelitis/chronic
fatigue
syndrome
(ME/CFS)
experience
core
symptoms
of
post-exertional
malaise,
unrefreshing
sleep,
and
cognitive
impairment.
Despite
numbering
0.2-0.4%
the
population,
no
laboratory
test
is
available
for
their
diagnosis,
effective
therapy
exists
treatment,
scientific
breakthrough
regarding
pathogenesis
has
been
made.
It
remains
unknown,
despite
decades
small-scale
studies,
whether
individuals
different
types
ME/CFS
separated
by
onset-type,
sex
or
age.
Annals of the Rheumatic Diseases,
Journal Year:
2024,
Volume and Issue:
83(6), P. 687 - 695
Published: Feb. 27, 2024
Messenger
RNA
(mRNA)
vaccines
as
a
novel
vaccine
platform
offer
new
tools
to
effectively
combat
both
emerging
and
existing
pathogens
which
were
previously
not
possible.
The
'plug
play'
feature
of
mRNA
enables
swift
design
production
targeting
complex
antigens
rapid
incorporation
constituents
needed.
This
makes
them
likely
be
adopted
for
widespread
clinical
use
in
the
future.Currently
approved
include
only
those
against
SARS-CoV-2
virus.
These
demonstrate
robust
immunogenicity
substantial
protection
severe
disease.
Numerous
viral
are
early
late
phase
development.
Several
influenza
tested
trials,
with
some
already
3
studies.
Other
phases
development
Viruses,
Journal Year:
2024,
Volume and Issue:
16(8), P. 1294 - 1294
Published: Aug. 14, 2024
The
acquisition
or
reactivation
of
Epstein–Barr
virus
(EBV)
after
allogeneic
Hematopoietic
Stem
Cell
Transplant
(HSCT)
can
be
associated
with
complications
including
the
development
post-transplant
lymphoproliferative
disorder
(PTLD),
which
is
significant
morbidity
and
mortality.
A
number
risk
factors
for
PTLD
have
been
defined,
T-cell
depletion,
approaches
to
monitoring
EBV,
especially
in
high-risk
patients,
use
preemptive
therapy
upon
viral
activation
described.
Newer
therapies
preemption
treatment
PTLD,
such
as
EBV-specific
cytotoxic
T-cells,
hold
promise.
Further
studies
help
define
risks,
diagnosis,
EBV-related
are
needed
this
at-risk
population.
